Focal adhesion kinase inhibitors, a heavy punch to cancer
Abstract Kinases are the ideal druggable targets for diseases and especially were highlighted on cancer therapy. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and its aberrant signaling extensively implicates in the progression of most cancer types, involving in cancer cell growth, a...
Guardado en:
Autores principales: | Yueling Wu, Ning Li, Chengfeng Ye, Xingmei Jiang, Hui Luo, Baoyuan Zhang, Ying Zhang, Qingyu Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Springer
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f8375424d64f46afbf8002a1c77b3cca |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Anastrozole Promotes Implantation by Altering the Expression of Paxillin and FAK in Rat Luminal Uterine Epithelium
por: Mwakikunga,Anthony, et al.
Publicado: (2020) -
Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
por: Ilaria Romito, et al.
Publicado: (2021) -
FAK Inhibition Attenuates Corneal Fibroblast Differentiation In Vitro
por: Vincent Yeung, et al.
Publicado: (2021) -
LIM domain-containing 2 (LIMD2) promotes the progress of ovarian cancer via the focal adhesion signaling pathway
por: Lixin Chen, et al.
Publicado: (2021) -
<named-content content-type="genus-species">Campylobacter jejuni</named-content> Triggers Signaling through Host Cell Focal Adhesions To Inhibit Cell Motility
por: Courtney M. Klappenbach, et al.
Publicado: (2021)